Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma

G. Corona, E. Vaccher, S. Sandron, I. Sartor, U. Tirelli, F. Innocenti, G. Toffoli

Research output: Contribution to journalArticlepeer-review

Abstract

The coadministration of protease inhibitors with anticancer drugs in the management of human immunodeficiency virus-related malignancies can cause potential drug-drug interactions. The effect of lopinavir/ritonavir (LPV/RTV) on the pharmacokinetics of irinotecan (CPT11) has been investigated in seven patients with Kaposi's sarcoma. Coadministration of LPV/RTV reduces the clearance of CPT11 by 47% (11.3±3.5 vs 21.3±6.3 l/h/m2, P=0.0008). This effect was associated with an 81% reduction (P=0.02) of the AUC (area under the curve) of the oxidized metabolite APC (7-ethyl-10-[4-N-(5- aminopentanoic-acid)-1-piperidino]-carbonyloxycamptothecin). The LPV/RTV treatment also inhibited the formation of SN38 glucuronide (SN38G), as shown by the 36% decrease in the SN38G/SN38 AUCs ratio (5.9±1.6 vs 9.2±2.6, P=0.002) consistent with UGT1A1 inhibition by LPV/RTV. This dual effect resulted in increased availability of CPT11 for SN38 conversion and reduced inactivation on SN38, leading to a 204% increase (P=0.0001) in SN38 AUC in the presence of LPV/RTV. The clinical consequences of these substantial pharmacokinetic changes should be investigated.

Original languageEnglish
Pages (from-to)601-606
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume83
Issue number4
DOIs
Publication statusPublished - Apr 2008

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma'. Together they form a unique fingerprint.

Cite this